Introduction
HIV-positive persons in Western countries now have an essentially normal life expectancy in the setting of effective antiretroviral therapy (ART). However, a major long-term concern in HIV includes accelerated atherosclerosis, as suggested by increased rates of coronary artery disease (CAD), stroke, and peripheral vascular disease, compared with HIV-negative persons. [1] [2] [3] Accelerated atherosclerosis in HIV may be related to pro-coagulant and pro-inflammatory mechanisms in the setting of immunosuppression, adverse viral effects on endothelial and other cells, deleterious metabolic effects of certain ART agents including dyslipidaemia and insulin resistance, a high prevalence of smoking and other substance use, and genetic factors. [4] [5] [6] Therefore, there has been considerable interest in early diagnosis of subclinical atherosclerosis in HIV-positive persons. Studies using carotid intima-media thickness (CIMT) measurement and coronary artery calcium (CAC) determination have not consistently shown an increased atherosclerosis prevalence in HIV-positive compared with HIV-negative persons, however. [7] [8] [9] Coronary artery disease may in part be non-calcified in patients aged <50 years, 10 and HIV-positive persons may experience cardiovascular events at a younger age than HIV-negative persons. 2 Coronary computed tomography angiography (CCTA) can accurately and reproducibly detect non-calcified plaque when compared with intravascular ultrasound, 11 and noncalcified plaque more accurately predicts cardiovascular events than CAC or CIMT. 12 In recent large CCTA studies from the USA, an increased 13 and a similar 14 prevalence of non-calcified plaque was identified in HIV-positive compared with HIV-negative persons. These inconsistent results, the lower CAD rates in middle/southern Europe compared to North America, 15, 16 and recent reports suggesting similar cardiovascular event rates in HIV-positive and HIVnegative non-smokers in Switzerland 17 and Denmark 18 highlight the need for additional studies.
The aims of our study were to compare the prevalence of subclinical atherosclerosis in HIV-positive and HIV-negative persons in Switzerland using CAC/CCTA, and to assess associations between cardiovascular risk factors, HIV infection, and subclinical CAD.
Methods

Study design and study participants
Enrolment was from 10/2013 to 7/2016. We investigated the association of HIV-infection with subclinical CAD by CCTA and non-contrast CT scan for calculating the CAC score. Enrolment criteria included age > _45 years, no documented CAD/stroke, GFR > _60 mL/min, no allergy to iodinated contrast agent, and no history of atrial fibrillation or other irregular heartbeat. HIV-positive persons were participants of the metabolism and aging core project of the Swiss HIV Cohort Study (www.shcs.ch). HIV-negative participants were referred for clinically indicated CCTA/ CAC during the enrolment period. We attempted to obtain comparable populations with regards to age, gender and Framingham risk score 16 by periodic comparisons of their characteristics and adjusting the selection criteria for HIV-negative individuals. The study was approved by the local ethics committees. Participants provided written informed consent; they had access to imaging results via their HIV physician and were offered management of any abnormality detected.
Data collection
For HIV-positive participants, data were collected within the SHCS, a prospective cohort study that has continuously enrolled HIV-positive adults since 1988. 19 Demographic, clinical, and laboratory data are collected every 6 months using a standardized protocol, including detailed information on cardiovascular events, hypertension, diabetes mellitus, smoking, alcohol and drug use, and medication. For HIV-negative participants, clinical information was obtained using a structured questionnaire that included indication for CCTA/CAC referral, verification of inclusion criteria, comorbidities, medication, smoking, alcohol, and drug use. Data were verified by chart review. Vital signs, fasting total, LDL-, HDL-cholesterol, triglycerides, glucose, and creatinine were measured at the time of CCTA/ CAC in all participants. 23 as plaque with positive remodelling (remodelling index > _1.1) and/or low attenuation plaque (< _30 HU). The segment involvement score (SIS) was calculated using one point for each coronary segment with any plaque. The segment severity score (SSS) was calculated using the total of all segments scored according to lesion severity. 24 Hypertension was defined as blood pressure > _140/90 mmHg or use of antihypertensive medication. Dyslipidaemia was defined as total cholesterol > _6.2 mmol/L, or HDL < _1.0 mmol/L in men (< _1.2 mmol/L in women), or use of lipid-lowering drugs. Diabetes mellitus was diagnosed with confirmed plasma glucose >7.0 mmol/L (fasting) or >11.1 mmol/L (non-fasting) or receiving antidiabetic medication. Alcohol consumption was assessed by using the Alcohol Use Disorders identification Test-Consumption. Undetectable HIV-RNA was defined as <50 copies/mL. Coronary age was calculated based on CAC score, age, sex, and ethnicity. 8 
Cardiac imaging
Statistical analysis
Characteristics of HIV-positive and HIV-negative participants were compared using the v 2 /Fisher's exact test for categorical and the Wilcoxon rank-sum test for continuous variables. To evaluate the association between HIV-infection and subclinical atherosclerosis, we used five separate dichotomous outcomes: (i) CAC score >0, (ii) any CCTA-detected plaque, (iii) calcified plaque, (iv) non-calcified/mixed plaque, and (v) high-risk plaque. Uni-and multivariable logistic regression models were used to explore the association between HIV and each outcome separately. Co-variables included HIV infection, sex, age, smoking, hypertension, dyslipidaemia, diabetes, and study centre. Subgroup analyses were done for females and for age groups 45-54, 55-64, and 65-74 years. In the analyses limited to HIV-positive participants we added CD4 nadir <50 cells/mL, HIV-1 RNA max >100 000 copies/mL, and ART duration to the models. In a sensitivity analysis, we used propensity scores for bias reduction in the selection of an unmatched control group. 25, 26 The propensity of being HIV positive was calculated by logistic regression (see Supplementary material online, Table S5 ). The score was then included as adjustment term in the logistic regression models, used both as untransformed linear variable, and after stratification into quintiles. All statistical analyses were done using Stata/SE 14.2 (StataCorp, College Station, TX, USA).
Results
Study population
A total of 704 study participants (median age 54 years, 83% men, 89% white, 428 HIV-positive, 276 HIV-negative) underwent both CAC determination and CCTA. Median effective radiation exposure was 1.8 mSv (IQR, 1.2-2.3). HIV-positive participants were asymptomatic. HIV-negative controls were asymptomatic (36.6%), had typical angina (8.3%), atypical chest pain (44.2%), or dyspnoea (10.9%). Baseline characteristics are shown in Table 1 . HIV-positive participants were more likely to be men, they were younger, and had lower BMI. Median Framingham risk scores and percentages of patients in the low, intermediate and high-risk categories were similar among HIVpositive and HIV-negative participants. HIV-positive participants had a lower prevalence of hypertension, diabetes, and dyslipidaemia, but were more likely to smoke and use drugs. Among the HIV-positive participants, men who had sex with men were the predominant group, 21% had prior AIDS-defining events, and 87% were on suppressive ART.
Prevalence of subclinical coronary artery disease
The prevalence of CAC score >0, median CAC scores and percentages of patients in different CAC score categories were similar in HIV-positive and HIV-negative participants ( Table 2 ). Figure 1 illustrates the similar age-specific CAC prevalence. Coronary computed tomography angiography showed a trend towards a lower prevalence of any coronary plaque in HIV-positive compared to HIVnegative participants, a lower prevalence of calcified plaque, and a similar prevalence of both non-calcified/mixed plaque, high-risk plaque, and coronary artery stenosis >50% and >70%. There were trends towards lower average SSS and SIS in HIV-positive participants.
Associations between cardiovascular risk factors, HIV infection and subclinical coronary artery disease
In univariable analysis, HIV showed trends towards lower SIS [odds ratio (OR) 0.78; 95% confidence interval (CI) 0.59-1.03; P = 0.08] and lower SSS (OR 0.77; 95% CI 0.59-1.02; P = 0.06) (Figure 2 , Supplementary material online, Table S1 ). HIV infection was not associated with CAC score >0 (OR 0.88; 95% CI 0.65-1.20; P = 0.42).
HIV infection was significantly associated with less calcified plaque (OR 0.62; 95% CI 0.46-0.84), with a trend towards less CCTAdetected plaque (OR 0.76; 95% CI 0.56-1.04; P = 0.09), but not with non-calcified/mixed plaque (OR 1.04; 95% CI 0.76-1.43; P = 0.78), or with high-risk plaque (OR 0.88; 95% CI 0.59-1.32, P = 0.54).
In the final multivariable model (Figure 2 , Supplementary material online, Table S1 ), HIV infection was associated with lower SIS [adjusted odds ratio (aOR) 0.72; 95% CI 0.53-0.99; P = 0.04] and lower SSS (aOR 0.71, 95% CI 0.52-0.97; P = 0.03). HIV was not associated with CAC >0 (aOR 0.79; 95% CI 0.55-1.14; P = 0.22). HIV was associated with less calcified plaque (aOR 0.57; 95% CI 0.40-0.82; P < 0.01), with a trend towards less CCTA-detected plaque (aOR 0.74; 95% CI 0.51-1.06; P = 0.10), but not with non-calcified/mixed plaque (aOR 1.01; 95% CI 0.70-1.46; P = 0.95), or high-risk plaque (aOR 0.94; 95% CI 0.59-1.49; P = 0.79).
Subgroup analyses in women
Results in women (n = 118) were consistent with the entire study population, but confidence intervals were wider (see Supplementary material online, Table S2 ). 
Subgroup analyses in different age groups
Results were consistent with the entire study population (Figure 1 , Supplementary material online, Table S3 ).
Associations between HIV-related variables and subclinical coronary artery disease
These associations were inconsistent (Figure 3 , Supplementary material online, Table S4 ). Advanced immunosuppression (CD4 nadir <50 cells/mL) was associated with non-calcified/mixed plaque. Maximum HIV viral load >100 000 copies/mL was associated with CAC >0, any plaque, and calcified plaque. Duration of antiretroviral treatment was associated with CAC >0.
Chronological and coronary age
HIV-negative participants [median age 56; interquartile range (IQR) 51-61 years] were older than HIV-positive participants (median age 52; IQR 49-57 years; P < 0.01), and had a higher coronary age (median 58.8, IQR 54.3-68.4 years) than HIV-positive participants (median 56.6, IQR 51-65.9 years; P < 0.01). However, the difference between coronary age and chronological age was similar in HIVnegative (mean difference 5.2 years; median difference 0; IQR 0-10 years) and HIV-positive participants (mean difference 5.5 years; median difference 0; IQR 0-10.6 years; P = 0.73).
Sensitivity analysis
There was no evidence of effect modification for any outcome by the propensity score which discriminated reasonably well between HIV-positive and HIV-negative participants. By including additional variables to those already included in the multivariable models, the c-statistic increased from 0.70 to 0.77 (see Supplementary material online, Table S5 ).
Discussion
To our knowledge, this is the first large-scale assessment of subclinical CAD in HIV-positive and HIV-negative persons from Europe. As expected, age, male sex, and traditional cardiovascular risk factors were significantly associated with subclinical CAD. HIV infection, however, did not independently contribute to CAC score, any plaque on CCTA, or non-calcified/mixed or high-risk plaque. On the contrary, HIV was associated with less calcified plaque and lower coronary SSS and SIS compared with the HIV-negative participants. Our findings appear robust, because results were consistent across different age groups and in both men and women. In addition, we found no evidence of advanced coronary age in our HIV-positive patients, and we were thus unable to confirm a previous report. 8 Our results differ from the results of a recent CCTA study conducted in the USA. Post et al. The association of cardiovascular events with duration of ART or advanced immunosuppression in the setting of HIV remains debated. 3, 6 We did not identify any association of ART duration with either calcified or non-calcified plaque, similar to the findings in noncocaine users by Lai et al., 14 and in contrast to MACS. 13 Consistent with MACS, 13 we found that low nadir CD4 count was associated with non-calcified plaque, potentially providing support for the now established recommendation for early initiation of ART. Our observation that CAC score and calcified plaque were associated with high pre-treatment levels of HIV viral load needs to be confirmed. Strengths of our study include this being the first large scale CAC/ CCTA evaluation comparing HIV-positive and HIV-negative persons in Europe, and that HIV-positive participants were followed in a wellestablished study, the SHCS. 19 Limitations include the cross-sectional nature and the absence of formal matching on cardiovascular risk factors of HIV-positive and HIV-negative participants in our study and in the two US studies. 13, 14 Thus, each of these studies' results are an indicator of how study participants were selected. However, we periodically adjusted selection criteria for the controls, resulting in comparable Framingham risk scores in the HIV-positive and HIVnegative participants, and we used propensity scores for bias reduction in the selection of an unmatched control group, which consistently showed comparable results for each of the imaging outcomes. HIV-negative controls were extensively matched on CAD risk factors to the HIV-positive participants in two previous studies, which showed no difference in CIMT progression 7 and a similar prevalence of non-calcified coronary plaque. 29 Our study included relatively few women and participants >65 years and therefore should be cautiously interpreted in these populations. Finally, even though we compared asymptomatic HIV-positive individuals with symptomatic HIVnegative CCTA referral patients, the similar prevalence of >50% coronary stenosis (see Table 2 ) documents that the symptoms that prompted CCTA referral of the controls were mostly of noncoronary origin. 30 Take home figure Subclinical atherosclerosis was associated with traditional cardiovascular risk factors in our study using coronary CT angiography, but not with HIV infection. HIV was associated with a similar prevalence of high risk plaque, lower prevalence of calcified plaque and lower coronary segment severity and involvement scores. HIV was not associated with more subclinical atherosclerosis in our study. Our findings appear to be consistent with recent reports that myocardial infarction rates were similar in HIV-positive and HIV-negative non-smokers in Denmark 18 and in Switzerland. 17 Taken together, these reports somewhat attenuate concerns about accelerated subclinical atherosclerosis in HIV-positive persons.
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